Stock Analiz

West Pharmaceutical Services Inc. (WST) financials: revenue, earnings and cash flow

Fiscal 2016–2025 + TTM · from SEC filings · data as of November 13, 2026

Summary

West Pharmaceutical Services’s revenue went from $1.5B in fiscal 2016 to $3.1B in fiscal 2025, growth of about 8.2% a year.

Net income in fiscal 2025 was $494M, a net margin of 16.1%; the best year in this period was 2021 with $662M.

Over the twelve months to September 30, 2026, revenue was $3.4B and net income $639M.

Free cash flow was $469M in fiscal 2025 and positive in 10 of the 10 years shown.

The diluted share count fell 3% over the period (buybacks).

Revenue, profit and cash flow by year

Revenue
2016: $1.5B162017: $1.6B172018: $1.7B182019: $1.8B192020: $2.1B202021: $2.8B212022: $2.9B222023: $2.9B232024: $2.9B242025: $3.1B25$3.1B
Net income
2016: $144M162017: $151M172018: $207M182019: $242M192020: $346M202021: $662M212022: $586M222023: $593M232024: $493M242025: $494M25$494M
Free cash flow
2016: $49M162017: $132M172018: $184M182019: $241M192020: $298M202021: $331M212022: $439M222023: $414M232024: $276M242025: $469M25$469M
EPS (diluted)
2016: $1.91162017: $1.99172018: $2.74182019: $3.21192020: $4.57202021: $8.67212022: $7.73222023: $7.88232024: $6.69242025: $6.7925$6.79

Income statement

Fiscal yearTTM2025202420232022202120202019201820172016
Revenue$3.4B$3.1B$2.9B$2.9B$2.9B$2.8B$2.1B$1.8B$1.7B$1.6B$1.5B
Gross profit$1.3B$1.1B$998M$1.1B$1.1B$1.2B$768M$606M$545M$513M$501M
Operating income$780M$585M$570M$676M$734M$752M$407M$297M$240M$226M$195M
Net income$639M$494M$493M$593M$586M$662M$346M$242M$207M$151M$144M
EPS (diluted)$8.91$6.79$6.69$7.88$7.73$8.67$4.57$3.21$2.74$1.99$1.91
R&D$76M$74M$69M$68M$58M$53M$47M$39M$40M$39M$37M
Revenue growth—+6.2%−1.9%+2.2%+1.9%+31.9%+16.7%+7.1%+7.4%+6.0%+7.8%

Cash flow

Fiscal yearTTM2025202420232022202120202019201820172016
Operating cash flow$654M$755M$653M$776M$724M$584M$472M$367M$289M$263M$219M
Capital spending-$201M-$286M-$377M-$362M-$285M-$253M-$174M-$126M-$105M-$131M-$170M
Free cash flow$453M$469M$276M$414M$439M$331M$298M$241M$184M$132M$49M
Dividends paid$63M$61M$59M$57M$54M$51M$48M$45M$42M$39M$36M
Buybacks$685M$134M$561M$438M$203M$137M$116M$83M$71M$74M$52M
Stock-based pay$28M$24M$19M$23M$24M$38M$34M$24M$15M$16M$20M

Balance sheet

Fiscal yearTTM2025202420232022202120202019201820172016
Cash—$791M$485M$854M$894M$763M$616M$439M$337M$236M$203M
Debt—$321M$302M$309M$318M$325M$326M$329M$196M$197M$229M
Equity—$3.2B$2.7B$2.9B$2.7B$2.3B$1.9B$1.6B$1.4B$1.3B$1.1B
Total assets—$4.3B$3.6B$3.8B$3.6B$3.3B$2.8B$2.3B$2.0B$1.9B$1.7B
Shares (diluted)71M73M74M75M76M76M76M75M75M76M75M

Margins and returns

Fiscal yearTTM2025202420232022202120202019201820172016
Gross margin37.6%35.9%34.5%38.3%39.4%41.5%35.8%32.9%31.8%32.1%33.2%
Operating margin23.0%19.0%19.7%22.9%25.4%26.6%18.9%16.1%14.0%14.1%12.9%
Net margin18.8%16.1%17.0%20.1%20.3%23.4%16.1%13.1%12.0%9.4%9.5%
FCF margin13.3%15.2%9.6%14.1%15.2%11.7%13.9%13.1%10.7%8.3%3.3%
ROIC—13.3%15.6%17.5%20.3%24.2%15.3%12.4%12.5%9.7%10.3%
ROE—15.5%18.4%20.6%21.8%28.3%18.7%15.4%14.8%11.8%12.8%

Frequently asked questions

What is West Pharmaceutical Services’s annual revenue?

$3.1B in fiscal 2025 and $3.4B over the twelve months to September 30, 2026.

How much profit does West Pharmaceutical Services make?

Net income was $494M in fiscal 2025 (net margin 16.1%).

Is West Pharmaceutical Services’s revenue growing?

Yes: revenue rose 6.3% in fiscal 2025 compared with the year before.

From the company’s 10-K and 10-Q filings with the SEC; per-share figures adjusted for stock splits. Rebuilt daily. Not investment advice.